Ask sales for the lot-numbered COA matched to the offered or supplied batch; it records the tests actually completed, their specifications, and the reported results.

Matching batch COA available.

PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →

FDA PCAC reviews 7 peptides in July. Read →

Sermorelin

Name: Sermorelin
Brand: PeptideXpo
SKU: sermorelin

GHRH 1-29 fragment

≥ 99.0%CAS 86168-78-7GH-Axis Peptides

PeptideXpo buyer fit

Sermorelin for distributor assortment and OEM sourcing comparison

This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Sermorelin inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.

Use this page when the buyer is comparing multiple SKUs, fill ladders, repeat-order economics, or distributor/OEM sourcing routes.
For regulated compounding-pharmacy qualification, a dedicated regulated-pharmacy channel should own the pharmacy-specific head keyword.
For research-lab method development, copper-chemistry, or cosmetic-formulation depth, the matching specialist channel (research standards, copper peptides, or cosmetic actives) should own the narrower specialist intent.

Overview

Sermorelin is the unmodified 29-amino-acid N-terminal fragment of native human GHRH (residues 1-29), retaining the full receptor-binding activity of the parent 44-residue molecule. Approved historically as a prescription drug (Geref) for pediatric GH deficiency diagnosis, Sermorelin is the most studied GHRH-receptor agonist and serves as the reference compound against which engineered analogues (CJC-1295, Tesamorelin, Modified GRF 1-29) are compared. The molecule's clinical pharmacokinetic limitation, a serum half-life of roughly 10-12 minutes due to DPP-4 cleavage at the Tyr1-Ala2 bond, is the design problem that motivated the substitution chemistry behind the CJC-1295 family. PeptideXpo supplies Sermorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 29-residue sequence is within reliable SPPS range and the analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion. Sermorelin is typically used in research contexts studying GHRH-receptor pharmacology at physiologically relevant time scales (the short half-life is a feature, not a bug, for pulse-pharmacology research) and in compounding workflows where the short-acting profile is appropriate. For sustained-action profiles, buyers generally route to CJC-1295 with DAC instead.

Who buys this, and why

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: 86168-78-7
Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 11-12 minutes
MOQ: On request
Lead time: 7–14 days
Storage: -20°C, protect from light

Documentation available on request

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Regulatory note

Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535.
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RGS. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.

Frequently asked questions

How does Sermorelin compare to CJC-1295 and Tesamorelin?▾

All three are GHRH-receptor agonists, but they differ in their pharmacokinetic engineering. Sermorelin is the unmodified GHRH(1-29) fragment with a roughly 10-minute serum half-life, the native molecule's properties. CJC-1295 (no DAC) adds four amino-acid substitutions that resist DPP-4 cleavage, extending half-life to roughly 30 minutes while retaining the physiological pulsatile signaling pattern. Tesamorelin adds an N-terminal trans-3-hexenoyl group, similarly improving protease resistance and extending half-life, Tesamorelin is the only FDA-approved member of this family, indicated for HIV-associated lipodystrophy. CJC-1295 with DAC sits at the far end of the half-life spectrum at roughly a week via albumin binding.

Why is Sermorelin's short half-life sometimes the preferred property?▾

Research workflows studying GHRH-receptor pharmacology often need to characterize pulsatile signaling at physiologically relevant timescales, sustained-elevation models produce different downstream biology than pulse-pattern models because GH-release feedback loops respond to pulse architecture, not just average exposure. Sermorelin's short half-life makes it the cleanest tool for studying pulse-pharmacology, dose-response within a single GH pulse, and acute receptor pharmacology. For sustained-elevation research or for clinical contexts where convenience matters, the longer-acting CJC-1295 (no DAC) or CJC-1295 with DAC are preferred.

Can Sermorelin be combined with a GHSR-pathway agonist like Ipamorelin?▾

Yes, the GHRH-pathway plus GHSR-pathway combination strategy applies to Sermorelin the same way it applies to CJC-1295: combining a GHRH-receptor agonist with a GHSR agonist produces additive GH-release magnitudes beyond either component alone. The Sermorelin + Ipamorelin combination is less common than CJC-1295 + Ipamorelin in published research and compounding workflows simply because CJC-1295's longer half-life better matches Ipamorelin's, but for short-pulse research applications the Sermorelin combination is mechanistically equivalent.

Related peptides

Buyers who view Sermorelin also ask about:

CJC-1295 (no DAC)

≥99.0%

Modified GRF 1-29 · GHRH analog

CAS: No single public CAS for the without-DACform; identity per batch COA
Vial: 2 mg–10 mg

MOQ on requestGet quote →

Ipamorelin

≥99.0%

Ghrelin / GHSR pathway GH-release peptide

CAS: 170851-70-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

57-mer

Tesamorelin

≥99.0%

GHRH analog · approved for HIV-associated lipodystrophy

CAS: 218949-48-5
Vial: 2 mg–20 mg

MOQ on requestGet quote →

See full catalog

Sermorelin

GHRH 1-29 fragment

≥ 99.0%CAS 86168-78-7GH-Axis Peptides

PeptideXpo buyer fit

Sermorelin for distributor assortment and OEM sourcing comparison

Use this page when the buyer is comparing multiple SKUs, fill ladders, repeat-order economics, or distributor/OEM sourcing routes.
For regulated compounding-pharmacy qualification, a dedicated regulated-pharmacy channel should own the pharmacy-specific head keyword.
For research-lab method development, copper-chemistry, or cosmetic-formulation depth, the matching specialist channel (research standards, copper peptides, or cosmetic actives) should own the narrower specialist intent.

Overview

Who buys this, and why

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: 86168-78-7
Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 11-12 minutes
MOQ: On request
Lead time: 7–14 days
Storage: -20°C, protect from light

Documentation available on request

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Regulatory note

Selected literature

Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535.
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RGS. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.

Frequently asked questions

How does Sermorelin compare to CJC-1295 and Tesamorelin?▾

Why is Sermorelin's short half-life sometimes the preferred property?▾

Can Sermorelin be combined with a GHSR-pathway agonist like Ipamorelin?▾

Related peptides

Buyers who view Sermorelin also ask about:

CJC-1295 (no DAC)

≥99.0%

Modified GRF 1-29 · GHRH analog

CAS: No single public CAS for the without-DACform; identity per batch COA
Vial: 2 mg–10 mg

MOQ on requestGet quote →

Ipamorelin

≥99.0%

Ghrelin / GHSR pathway GH-release peptide

CAS: 170851-70-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

57-mer

Tesamorelin

≥99.0%

GHRH analog · approved for HIV-associated lipodystrophy

CAS: 218949-48-5
Vial: 2 mg–20 mg

MOQ on requestGet quote →

See full catalog